Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease
- 26 March 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (6), 2915-2929
- https://doi.org/10.1021/acs.jmedchem.9b01439
Abstract
To identify Janus kinase (JAK) inhibitors that selectively target gastrointestinal tissues with limited systemic exposures, a class of imidazopyrrolopyridines with a range of physical properties was prepared and evaluated. We identified compounds with low intrinsic permeability and determined a correlation between permeability and physicochemical properties, clogP and tPSA, for a subset of compounds. This low intrinsic permeability translated into compounds displaying high colonic exposure and low systemic exposure after oral dosing at 25 mg/kg in mouse. In a mouse PK/PD model, oral dosing of lead compound 2 demonstrated dose-dependent inhibition of pSTAT phosphorylation in colonic explants post-oral dose but low systemic exposure and no measurable systemic pharmacodynamic activity. We thus demonstrate the utility of JAK inhibitors with low intrinsic permeability as a feasible approach to develop gut-restricted, pharmacologically active molecules with a potential advantage over systemically available compounds that are limited by systemic on-target adverse events.This publication has 26 references indexed in Scilit:
- Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel SyndromeAdvances in Therapy, 2013
- JAKs and STATs in Immunity, Immunodeficiency, and CancerNew England Journal of Medicine, 2013
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Library Enhancement through the Wisdom of CrowdsJournal of Chemical Information and Modeling, 2011
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placeboArthritis & Rheumatism, 2009
- Biopharmaceutics Classification System: Validation and Learnings of an in Vitro Permeability AssayMolecular Pharmaceutics, 2008
- Global mapping of pharmacological spaceNature Biotechnology, 2006
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 2001
- MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability ScreeningJournal of Pharmaceutical Sciences, 1999